

SCIENTIFIC PROGRAM (as of June 05, 2017)

Tuesday, June 13, 2017

- 08:00 – 17:30
Auditorium
(Lugano University) **CLOSED WORKSHOP - DESIGN OF CLINICAL TRIALS: BIOLOGICAL AND CLINICAL ENDPOINTS IN THE DESIGN OF FUTURE CLINICAL TRIALS**
Co-chairs: A. Younes, New York, NY (USA) and E. Zucca, Bellinzona (Switzerland)
Organized in co-operation with American Association for Cancer Research – AACR and European School of Oncology – ESO
by invitation only
- 15:00 – 17:30
Aula Magna
(Lugano University) **WORKSHOP - NOVEL ISSUES IN THE COMBINED MODALITY TREATMENT OF LYMPHOMAS**
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)
Organized by International Lymphoma Radiation Oncology Group - ILROG
open to all 14-ICML attendees
- 15:00 **PART 1: IMMUNOMODULATORY TREATMENT IN THE COMBINED MODALITY SETTING**
IMMUNOMODULATORY TREATMENT AND RADIATION THERAPY IN LYMPHOMAS
T.M. Illidge, Manchester (UK)
- 15:15 IMMUNOMODULATORY TREATMENT, ALONE OR IN COMBINATION WITH OTHER TREATMENT MODALITIES IN THE TREATMENT OF LYMPHOMAS
C. Moskowitz, New York, NY (USA)
- 15:30 GENERATING AN ABCOPAL EFFECT BY RADIOTHERAPY FOLLOWED BY CHECKPOINT INHIBITORS IN INDOLENT LYMPHOMAS
M.L. Palomba, New York, NY (USA)
- 15:45 PANEL DISCUSSION
T.M. Illidge, Manchester (UK), C. Moskowitz, New York, NY (USA), M.L. Palomba, New York, NY (USA), M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)
- 16:00 - 16:30 **COFFEE BREAK** - inside Aula Magna (Lugano University) for workshop attendees
- 16:30 **PART 2: NK/T-CELL LYMPHOMAS, AN EMERGING LYMPHOMA TYPE WITH SPECIAL ISSUES**
NK/T-CELL LYMPHOMAS IN ASIA. TREATMENT PRINCIPLES. WHAT RADIATION THERAPY? WHAT CHEMOTHERAPY REGIMEN? WHEN TO COMBINE AND WHEN TO USE SINGLE MODALITY?
M. Oguchi, Tokyo (Japan)
- 16:45 NK/T-CELL LYMPHOMAS IN THE WESTERN WORLD. EXPERIENCE WITH COMBINED MODALITY TREATMENT AT MSKCC
S.M. Horwitz, New York, NY (USA)
- 17:00 THE BEIJING EXPERIENCE WITH RADIATION ALONE
Y.-X. Li, Beijing (China)
- 17:15 PANEL DISCUSSION
M. Oguchi, Tokyo (Japan), S.M. Horwitz, New York, NY (USA), Y.-X. Li, Beijing (China), L. Specht, Copenhagen (Denmark) and M.K. Gospodarowicz, Toronto (Canada)

Wednesday, June 14, 2017

08:30 – 12:00 Marquee	POSTER SESSION SET UP
08:30 – 09:15	“MEET THE PROFESSOR” SESSIONS 🎤 <i>5 parallel sessions</i>
Room A	CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS J.W. Friedberg, Rochester, NY (USA) <i>repeated on Thursday, June 15, in Aula Magna (Lugano University)</i>
Room B and Marquee	THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS L. Quintanilla-Martinez, Tuebingen (Germany) <i>repeated on Friday, June 16 in Cinema Corso</i>
Cinema Corso	ROLE AND TIMING OF NEW DRUGS IN CLL M. Hallek, Cologne (Germany) <i>repeated on Friday, June 16, in Room A</i>
Auditorium (Lugano University)	THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017 J.G. Gribben, London (UK) <i>repeated today at 09:30 in Auditorium (Lugano University)</i>
Aula Magna (Lugano University)	THE COSTS OF CARE IN HAEMATOLOGICAL CANCERS: HEALTH ECONOMIC ISSUES M.F. Fey, Bern (Switzerland) <i>offered only once</i>
09:30 – 10:15	<i>5 parallel sessions</i>
Room A	RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA P.W.M. Johnson, Southampton (UK) <i>repeated on Thursday, June 15, in Cinema Corso</i>
Room B and Marquee	DISEASE-ORIENTED TREATMENT OF T-CELL LYMPHOMAS K. Tobinai, Tokyo (Japan) <i>offered only once</i>
Cinema Corso	CLINICAL APPLICATIONS OF GENOME STUDIES A. Younes, New York, NY (USA) <i>repeated on Thursday, June 15, in Room B</i>
Auditorium (Lugano University)	THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017 J.G. Gribben, London (UK)
Aula Magna (Lugano University)	THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS M. Raderer, Vienna (Austria) <i>repeated on Friday, June 16, in Room B</i>
10:15 – 10:35 Marquee	COFFEE BREAK

10:35 – 12:00

EDUCATIONAL SYMPOSIA 🏢

2 parallel sessions

Room A, Cinema Corso
and Aula Magna
(Lugano University)

AGGRESSIVE LYMPHOMAS
Chair: E. Campo, Barcelona (Spain)

MOLECULAR GENETICS OF AGGRESSIVE B CELL LYMPHOMAS
R. Dalla-Favera, New York, NY (USA)
PATHOLOGY AND CLASSIFICATION OF AGGRESSIVE MATURE B-CELL
LYMPHOMAS
E. Campo, Barcelona (Spain)
TREATMENT OF AGGRESSIVE B-CELL LYMPHOMAS
S.M. Smith, Chicago, IL (USA)

Room B
and Marquee

IMMUNOTHERAPY IN LYMPHOMAS
Chair: S.M. Ansell, Rochester, MN (USA)

IMMUNOLOGY
F. Caligaris-Cappio, Milan (Italy)
CAR T-CELLS
D.G. Maloney, Seattle, WA (USA)
CHECKPOINT INHIBITORS
S.M. Ansell, Rochester, MN (USA)

12:00 – 18:30
Marquee

Abstract
number

POSTER SESSION

(printing and delivery of the posters sponsored by Takeda Oncology)

140 - 163	PATHOLOGY AND BIOLOGY
164 - 177	HODGKIN LYMPHOMA
178 - 204	AGGRESSIVE LYMPHOMAS
205 - 214	MANTLE CELL LYMPHOMA
215 - 234	INDOLENT LYMPHOMAS
235 - 241	CLL
242 - 257	NK and T-CELL LYMPHOMAS
258 - 289	NEW DRUG DEVELOPMENT

12:00 – 13:00
Marquee

LUNCH TIME AND POSTER VIEWING

13:00 – 14:00
Room A, B, Marquee,
Cinema Corso and
Aula Magna
(Lugano University)

OPENING OF THE CONFERENCE 🏢

WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)

HENRY KAPLAN MEMORIAL LECTURE AND ICML PRIZE 🏢

Laudatio: A. Lanzavecchia, Bellinzona (Switzerland)

001

IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS
R. Levy, Stanford, CA (USA)

14:00 – 15:15

Room A, B, Marquee,
Cinema Corso and
Aula Magna
(Lugano University)

PLENARY SESSION

Co-chairs: J.M. Vose, Omaha, NE (USA) and J.W. Friedberg, Rochester, NY (USA)

14:00 004 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
F. Morschhauser, Lille (France)

14:15 Discussant: T.E. Witzig, Rochester, MN (USA)

14:25 005 CRISPR-Cas9 GENETIC SCREENS UNCOVER A B CELL RECEPTOR-MYD88 SUPERPATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA
R.M. Young, Bethesda, MD (USA)

14:40 Discussant: R. Dalla-Favera, New York, NY (USA)

14:50 006 BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
P. Cramer, Cologne (Germany)
Best Abstract Merit Award, sponsored by Swiss Cancer League Foundation

15:05 Discussant: D. Rossi, Bellinzona (Switzerland)

15:15 – 15:40

Marquee, Cinema Corso
and Aula Magna
(Lugano University)

COFFEE BREAK

15:40 – 16:40

Room A, B, Marquee,
Cinema Corso and
Aula Magna
(Lugano University)

AACR-ICML JOINT SESSION - CANCER IMMUNOTHERAPY

Co-chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)

15:40 007 GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
S.J. Schuster, Philadelphia, PA (USA)

15:55 008 AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1
S.S. Neelapu, Houston, TX (USA)

16:10 009 WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA?
A.M.M. Eggermont, Villejuif (France)

16:25 010 WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER?
R. Stahel, Zurich (Switzerland)

16:40 – 17:00

BREAK

17:00 – 18:00

“FOCUS ON...” SESSIONS

5 parallel sessions

Room A

CLASSICAL THERAPIES FOR FOLLICULAR LYMPHOMA

Chair: A.T. Lister, London (UK)

- 17:00 011 OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF ¹⁸F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG
J.L. Brady, London (UK)
- 17:10 012 CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL
M.P. MacManus, Melbourne (Australia)
- 17:20 013 RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO
E. Hoster, Munich (Germany)
- 17:30 014 DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL
R. Pettengell, London (UK)
- 17:40 015 LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY
S. Luminari, Reggio Emilia (Italy)
- 17:50 016 CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
C. Sarkozy, Pierre Bénite (France)

Room B
and Marquee

PET/CT: VISUAL ASSESSMENT AND BEYOND

Chair: B.D. Cheson, Washington D.C. (USA)

- 17:00 017 PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL
A. Cottreau, Paris (France)
- 17:10 018 BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE
A.J. Moskowitz, New York, NY (USA)
- 17:20 019 CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033)
L.C. Pike, London (UK)
- 17:30 020 CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)
L. Rigacci, Florence (Italy)

17:40	021	PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY J. Trotman, Sydney (Australia)
17:50	022	FDG-PET AS A BIOMARKER OF RESPONSE IN DLBCL: THE HOVON 84 STUDY EXPERIENCE C.N. Burggraaff, Amsterdam (The Netherlands)
Cinema Corso		CLINICO-PATHOLOGICAL CORRELATIONS Chair: E.S. Jaffe, Bethesda, MD (USA)
17:00	023	NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA C. Sarkozy, Pierre Bénite (France)
17:10	024	<i>FOXP1</i> EXPRESSION IS INVERSELY CORRELATED WITH <i>EZH2</i> MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY A. Mottok, Vancouver (Canada)
17:20	025	ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R-CHOP C. Keane, Woolloongabba (Australia)
17:30	026	CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY M. Klanova, Prague (Czech Republic)
17:40	027	NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY M. Cheminant, Paris (France)
17:50	028	ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF EPSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER K. Kawamoto, Kurume (Japan)
Auditorium (Lugano University)		NOVEL ANTI-LYMPHOMA DRUGS Chair: T.E. Witzig, Rochester, MN (USA)
17:00	029	PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION D. Weber, Basel (Switzerland)
17:10	030	ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA P. Pérez-Galán, Barcelona (Spain)
17:20	031	A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY S. Le Guill, Nantes (France)
17:30	032	PHASE I STUDY OF IPH4102, ANTI-KIR3DL2 MAB, IN RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMAS (CTCL): DOSE-ESCALATION SAFETY, BIOMARKER AND CLINICAL ACTIVITY RESULTS Y.H. Kim, Stanford, CA (USA)

17:40	033	A PHASE 1 STUDY OF THE ANTI-CD37 ANTIBODY-DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS A. Sawas, New York, NY (USA)
17:50	034	FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL B.S. Kahl, St. Louis, MO (USA)
Aula Magna (Lugano University)		CHEMOTHERAPY-FREE COMBINATIONS Chair: S.M. Smith, Chicago, IL (USA)
17:00	035	FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA P. Martin, New York, NY (USA)
17:10	036	L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY G. Salles, Lyon (France)
17:20	037	A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA F. Morschhauser, Lille (France)
17:30	038	PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL) J.M. Michot, Villejuif (France)
17:40	039	PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA C. Batlevi, New York, NY (USA)
17:50	040	UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL M.S. Davids, Boston, MA (USA)

Thursday, June 15, 2017

08:00 – 08:45

MEET THE PROFESSOR SESSIONS

5 parallel sessions

Room A

MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS

C. Thieblemont, Paris (France)

repeated on Friday, June 16, in Aula Magna (Lugano University)

Room B
and Marquee

CLINICAL APPLICATIONS OF GENOME STUDIES

A. Younes, New York, NY (USA)

Cinema Corso

RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA

P.W.M. Johnson, Southampton (UK)

Auditorium (Lugano University)		ALCL AND PTCL: WHAT CAN PEDIATRIC AND ADULT ONCOLOGISTS LEARN FROM EACH OTHER? L. Brugières, Villejuif (France) and F. D'Amore, Aarhus (Denmark) <i>offered only once</i>
Aula Magna (Lugano University)		CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS J.W. Friedberg, Rochester, NY (USA)
08:30 – 18:30 Marquee		POSTER SESSION
09:00 – 10:30		“CASE DISCUSSION” SESSIONS: California vs Germany <i>4 parallel sessions</i>
Room A		HODGKIN LYMPHOMA Chair: C. Moskowitz, New York, NY (USA) Discussants: R.H. Advani, Stanford vs P. Borchmann, Cologne
Cinema Corso		T-CELL LYMPHOMAS Chair: J.M. Vose, Omaha, NE (USA) Discussants: L.C. Pinter-Brown, Orange vs G. Wulf, Goettingen
Auditorium (Lugano University)		PEDIATRIC AND ADOLESCENT LYMPHOMAS Chair: W. Wössmann, Giessen (Germany) Discussants: C. Bollard, Washington, DC vs B. Burkhardt, Muenster
Aula Magna (Lugano University)		RADIOTHERAPY FOR LYMPHOMAS Chair: L. Specht, Copenhagen (Denmark) Discussants: R.T. Hoppe, Stanford vs G. Mikhaeel, London (UK)
09:00 – 10:30 Room B and Marquee	Abstract number	SESSION 1 – LYMPHOMA BIOLOGY Co-chairs: R. Küppers, Essen (Germany) and M.A. Shipp, Boston, MA (USA)
09:00	041	GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA A. Fama, Rochester, MN (USA)
09:15	042	DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS S. Dietrich, Heidelberg (Germany)
09:30	043	ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) V. Priebe, Bellinzona (Switzerland)
09:45	044	<i>NOTCH1</i> MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS F. Pozzo, Aviano (Italy)
10:00	045	ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA M. Sakata-Yanagimoto, Ibaraki (Japan)
10:15	046	TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA R.L. Boddicker, Rochester, MN (USA)

10:30 – 11:00
Marquee

COFFEE BREAK

11:00 – 12:00
Room A, B, Marquee,
Cinema Corso and Aula
Magna (Lugano University)

SESSION 2 – PRIMARY MEDIASTINAL B-CELL LYMPHOMA

Co-chairs: A.J. Davies, Southampton (UK) and G.S. Nowakowski, Rochester, MN (USA)

- 11:00 047 MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT
A. Mottok, Vancouver (Canada)
- 11:15 048 METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA
L. Ceriani, Bellinzona (Switzerland)
- 11:30 049 OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: A MULTICENTER RETROSPECTIVE ANALYSIS
L.G. Roth, New York, NY (USA)
- 11:45 050 EFFICACY AND SAFETY OF PEMBROLIZUMAB IN RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (rrPMBCL): INTERIM ANALYSIS OF THE KEYNOTE-170 PHASE 2 TRIAL
P.L. Zinzani, Bologna (Italy)

12:00 – 13:00
Marquee

LUNCH TIME AND POSTER VIEWING

from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45
Room A, B,
Marquee,
Cinema Corso
and Aula Magna
(Lugano
University) 002

GIANNI BONADONNA MEMORIAL LECTURE 📺

Chair: R. Dalla-Favera, New York, NY (USA)

sponsored by American Association for Cancer Research – AACR

GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES
M.A. Shipp, Boston, MA (USA)

13:15 – 16:45
Auditorium
(Lugano University)

WORKSHOP - CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES

Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and J. Yahalom, New York, NY (USA)
Organized by International Lymphoma Radiation Oncology Group – ILROG

open to all 14-ICML attendees

13:15
13:30
13:45

MY INDICATIONS FOR RADIATION THERAPY IN THE PRIMARY TREATMENT OF HODGKIN AND NON HODGKIN LYMPHOMAS

A.K. Ng, Boston, MA (USA)

C. Thieblemont, Paris (France)

U. Ricardi, Turin (Italy)

14:00

Case oriented discussion: A.K. Ng, Boston (USA), C. Thieblemont, Paris (France), U. Ricardi, Turin (Italy), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)

14:15 – 14:25

BREAK

14:25
14:40
14:55

MY INDICATIONS FOR RADIATION THERAPY IN RELAPSED/REFRACTORY HODGKIN AND NON HODGKIN LYMPHOMAS

J. Yahalom, New York, NY (USA)

G. Salles, Lyon (France)

G. Mikhaeel, London (UK)

- 15:10 Case oriented discussion: J. Yahalom, New York, NY (USA), G. Salles, Lyon (France), G. Mikhaeel, London (UK) and M.K. Gospodarowicz, Toronto (Canada)
- 15:25 – 15:45 **COFFEE BREAK** - inside Auditorium (Lugano University) for workshop attendees
- 15:45 APPROACHES TO REDUCE LATE EFFECTS OF LYMPHOMA TREATMENT
B.S. Dabaja, Houston, TX (USA): IS PROTON THERAPY THE ANSWER?
- 16:00 D. Hodgson, Toronto (Canada): STRATEGIES TO REDUCE THE RISK OF SECOND MALIGNANCIES
- 16:15 L. Specht, Copenhagen (Denmark): STRATEGIES TO REDUCE THE RISK OF CARDIOVASCULAR LATE EFFECTS
- 16:30 Discussion: B.S. Dabaja, Houston, TX (USA), D. Hodgson, Toronto (Canada), L. Specht, Copenhagen (Denmark), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)
- 13:45 – 15:15 **SESSION 3 – HODGKIN LYMPHOMA**
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)
Co-chairs: V. Diehl, Cologne (Germany) and A. Pavlovsky, Buenos Aires (Argentina)
- 13:45 051 RESTORE & TARGET: A CONCEPTUALLY NOVEL TREATMENT APPROACH TO CLASSICAL HODGKIN'S LYMPHOMA
C. Schmitt, Berlin (Germany)
- 14:00 052 GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY
A. Bruscazzin, Bellinzona (Switzerland)
- 14:15 053 eBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM-PET-POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL
P. Borchmann, Cologne (Germany)
- 14:30 054 RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER A NEGATIVE INTERIM PET SCAN (CRUK/07/033)
J. Trotman, Concord (Australia)
- 14:45 055 BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (cHL)
R. Chen, Duarte, CA (USA)
- 15:00 056 COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS
B.M. Aleman, Amsterdam (The Netherlands)
- 15:15 – 15:30 **COFFEE BREAK**
Marquee, Cinema Corso and Aula Magna (Lugano University)

15:30 – 17:00 2 parallel sessions

15:30 – 17:00
Room A, Cinema Corso
and Aula Magna
(Lugano University)

SESSION 4 – TARGETING THE BCR PATHWAYS

Co-chairs: J.F. Seymour, Melbourne (Australia) and C. Thieblemont, Paris (France)

- 15:30 057 CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM A PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
G. Lenz, Muenster (Germany)
- 15:45 058 DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
P.L. Zinzani, Bologna (Italy)
- 16:00 059 BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
J. Trotman, Concord (Australia)
- 16:15 060 IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK
C. Soussain, Saint-Cloud (France)
- 16:30 061 TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF A PHASE 1 STUDY
J. Kaplan, Chicago, IL (USA)
- 16:45 062 THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES
P.A. Hamlin, Basking Ridge, NJ (USA)
- 15:30 – 17:00
Room B and Marquee
- SESSION 5 – T-CELL LYMPHOMAS**
Co-chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)
- 15:30 063 GENE EXPRESSION PROFILING USING A RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T-CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLs-NOS
P. Ruminy, Rouen (France)
- 15:45 064 CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA: INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL
M. Gleeson, Sutton (UK)
- 16:00 065 ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA: A PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS
G. Fossard, Pierre Bénite (France)
- 16:15 066 BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION
Y.H. Kim, Stanford, CA (USA)

16:30	067	IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA; DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT C.P. Fox, Nottingham (UK)
16:45	068	GAD-M REGIMEN FOR NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA: ANALYSIS OF EFFICACY AND SAFETY FROM PHASE II STUDY (NCT 01991158) Z. Li, Guang Zhou (China)
17:00 -17:15		BREAK
17:15 – 18:15		“FOCUS ON...” SESSIONS <i>5 parallel sessions</i>
Room A		TARGETING CD30 IN HODGKIN LYMPHOMA Chair: A. Engert, Cologne (Germany)
17:15	069	RESULTS OF A PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY) A. Gibb, Manchester (UK)
17:25	070	BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM A PHASE 2 CLINICAL TRIAL S.I. Park, Charlotte, NC (USA)
17:35	071	RESULTS OF A MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAIVE SETTING T.A. Eyre, Oxford (UK)
17:45	072	BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY A. Bazarbachi, Beirut (Lebanon)
17:55	073	SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412) C.S. Diefenbach, New York, NY (USA)
18:05	074	INTERIM RESULTS FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA A.F. Herrera, Duarte, CA (USA)
Room B and Marquee		NOVEL ANTI-LYMPHOMA STRATEGIES Chair: P.W.M. Johnson, Southampton (UK)
17:15	075	CLARITHROMYCIN AS A “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) A.J. Ferreri, Milan (Italy)
17:25	076	A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) J.E. Amengual, New York, NY (USA)

- 17:35 077 CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP
J. Kuruvilla, Kingston (Canada)
- 17:45 078 EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL
A. Pettitt, Liverpool (UK)
- 17:55 079 VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF A PHASE I STUDY
L.J. Swinnen, Baltimore, MD (USA)
- 18:05 080 POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
H. Tilly, Rouen (France)

Cinema Corso

CLINICO-GENETIC RISK MODELS

Chair: P. Gaulard, Créteil (France)

- 17:15 081 APPLICATION OF A GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)
C.H. Burton, Leeds (UK)
- 17:25 082 THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
D.W. Scott, Vancouver (Canada)
- 17:35 083 GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP
I. Dlouhy, Barcelona (Spain)
- 17:45 084 KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL
S. Ferrero, Turin (Italy)
- 17:55 085 BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA
M.H. Delfau-Larue, Creteil (France)
- 18:05 086 EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL
S. Huet, Pierre Bénite (France)

Auditorium
(Lugano University)

ONGOING TRIALS

Chair: M. Dreyling, Munich (Germany)

- 17:15 OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING
A. Chiappella, Turin (Italy)

17:25	OT02	PHASE II STUDY OF DURVALUMAB (ANTI-PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA U. Jäger, Vienna (Austria)
17:35	OT03	CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA L. Nayak, Boston, MA (USA)
17:45	OT04	MCL-R2 ELDERLY: A PHASE III STUDY OF THE <i>EUROPEAN MCL NETWORK</i> ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND A RITUXIMAB-LENALIDOMIDE MAINTENANCE V. Ribrag, Villejuif (France)
17:55	OT05	PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) C.S. Tam, Melbourne (Australia)
18:05	OT06	A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA C. Buske, Ulm (Germany)
Aula Magna (Lugano University)		LYMPHOMA IN THE ELDERLY Chair: U. Vitolo, Turin (Italy)
17:15	087	HIGHER AGE IS ASSOCIATED WITH INCREASED MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA S. Alig, Munich (Germany)
17:25	088	LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE. A LYSA STUDY M.H. Delfau-Larue, Creteil (France)
17:35	089	CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP O. Al-Sawaf, Cologne (Germany)
17:45	090	UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY – A POPULATION-BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973-2014 M. Björkholm, Stockholm (Sweden)
17:55	091	TREATMENT STRATEGIES AND OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA OF THE ELDERLY: A DANISH POPULATION-BASED COHORT STUDY OF 1,011 PATIENTS M.B. Juul, Odense (Denmark)
18:05	092	REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP C. Thieblemont, Paris (France)

Friday, June 16, 2017

08:00 – 08:45		MEET THE PROFESSOR SESSIONS 🎤 <i>5 parallel sessions</i>
Room A		ROLE AND TIMING OF NEW DRUGS IN CLL M. Hallek, Cologne (Germany)
Room B and Marquee		THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS M. Raderer, Vienna (Austria)
Cinema Corso		THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS L. Quintanilla-Martinez, Tuebingen (Germany)
Auditorium (Lugano University)		LATE SEQUELAE IN HODGKIN LYMPHOMA SURVIVORS F.E. Van Leeuwen, Amsterdam (The Netherlands) <i>offered only once</i>
Aula Magna (Lugano University)		MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS C. Thieblemont, Paris (France)
08:30 – 18:30 Marquee		POSTER SESSION
09:00 – 10:30		“CASE DISCUSSION” SESSIONS: California vs Germany <i>4 parallel sessions</i>
Room A		AGGRESSIVE LYMPHOMAS Chair: S. Le Gouill, Nantes (France) Discussants: S. De Vos, Santa Monica vs G. Lenz, Muenster
Cinema Corso		INDOLENT LYMPHOMAS Chair: A. Lopez-Guillermo, Barcelona (Spain) Discussants: T. J. Kipps, La Jolla vs M. Dreyling, Munich
Auditorium (Lugano University)		CLL Chair: J.G. Gribben, London (UK) Discussants: S.M. O'Brien, Orange vs S. Stilgenbauer, Ulm
Aula Magna (Lugano University)		DIFFICULT PATHOLOGICAL CASES Chair: M. Ghielmini, Bellinzona (Switzerland) Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland), L. Quintanilla-Martinez, Tuebingen (Germany) Discussants: S.T. Rosen, Duarte vs U. Dührsen, Essen
09:00 – 10:30 Room B and Marquee		SESSION 6 – LYMPHOMA GENOMICS Co-chairs: A. Melnick, New York, NY (USA) and W.-L. Zhao, Shanghai (China)
09:00	093	A SINGLE-CELL BASED MODEL EXPLAINS PATTERNS OF CLONAL EVOLUTION IN PRIMARY AND RELAPSED FOLLICULAR LYMPHOMA M. Löffler, Leipzig (Germany)
09:15	094	FULL TRANSCRIPTOME SEQUENCING OF SORTED HODGKIN AND REED-STERNBERG CELLS REVEALS PLASMACYTIC DIFFERENTIATION, INSIGHTS INTO MECHANISMS OF ONCOGENESIS AND IMMUNE EVASION M. Roshal, New York, NY (USA)

09:30	095	PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINICAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML, ICGC AND BLUEPRINT CONSORTIA R. Wagener, Ulm (Germany)
09:45	096	MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B-CELL LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML-SEQ CONSORTIUM D. Huebschmann, Heidelberg (Germany)
10:00	097	CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN A CLINICAL LABORATORY SETTING S. Barrans, Leeds (UK)
10:15	098	THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE F. Jardin, Rouen (France)
10:30 – 10:50 Marquee		COFFEE BREAK
10:50 – 12:05 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)		SESSION 7 – ADVANCES IN CLL Co-chairs: N. Chiorazzi, Manhasset, NY (USA) and B. Eichhorst, Cologne (Germany)
10:50	099	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49d: CLINICAL RELEVANCE E. Tissino, Aviano (Italy)
11:05	100	INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS T.J. Kipps, La Jolla, CA (USA)
11:20	101	UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY A. Mato, Philadelphia, PA (USA)
11:35	102	CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL L.J. Nastoupil, Houston, TX (USA)
11:50	103	SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) C.S. Tam, Melbourne (Australia)
12:05 – 13:00 Marquee		LUNCH TIME AND POSTER VIEWING <i>from 12:30 to 13:00 authors in front of their poster for discussion with attendees</i>
13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna		JOHN ULTMANN MEMORIAL LECTURE 🎤 Chair: E. Campo, Barcelona (Spain) <i>sponsored by European School of Oncology – ESO</i>

(Lugano University)	003	GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS R. Siebert, Ulm (Germany)
		<i>3 parallel sessions</i>
13:45 – 15:15 Room A, B, Marquee and Cinema Corso		SESSION 8 – FOLLICULAR LYMPHOMA Co-chairs: B.S. Kahl, St. Louis, MO (USA) and E. Kimby, Stockholm (Sweden)
13:45	104	GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA S. Huet, Pierre Bénite (France)
14:00	105	THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB. THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE M. Federico, Modena (Italy)
14:15	106	PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: A POOLED ANALYSIS FROM LYSA AND FIL TRIALS A. Cottreau, Paris (France)
14:30	107	IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN W. Hiddemann, Munich (Germany)
14:45	108	COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1) M. Dreyling, Munich (Germany)
15:00	109	HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY L.J. Nastoupil, Houston, TX (USA)
14:15 – 17:15 Auditorium (Lugano University)		IBSA FOUNDATION SPECIAL FORUM - BASIC MECHANISMS OF CANCER IMMUNOTHERAPY Chair: A. Alimonti, Bellinzona (Switzerland) Organized by IBSA Foundation for Scientific Research open to all 14-ICML attendees, appreciated pre-registration at www.ibsafoundation.org (free session)
14:15		WELCOME S. Misiti, Lugano (Switzerland)
14:20		INTRODUCTION A. Alimonti, Bellinzona (Switzerland)
14:30		IMMUNOTHERAPY HAS COME OF AGE R. Levy, Stanford, CA (USA)
15:00		IMMUNOGENIC CELL DEATH: EXPLAINING THE SUCCESS OF CANCER THERAPIES G. Kroemer, Paris (France)
15:30 – 16:00		COFFEE BREAK - inside Auditorium (Lugano University) for attendees

16:00		WHY THE IMMUNE RESPONSE IN LYMPHOMA IS INADEQUATE F. Caligaris-Cappio, Milan (Italy)
16:30		PRE-CLINICAL DEVELOPMENT OF NOVEL COMBINATORIAL THERAPIES AGAINST MYC/BCL2 DOUBLE-HIT LYMPHOMA B. Amati, Milan (Italy)
14:15 – 17:05 Aula Magna (Lugano University)		UCLI-ICML JOINT SESSION - NATURAL KILLER / T-CELL (NK/T-CELL) LYMPHOMA Co-chairs: J.M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China) and Y.-K. Shi, Beijing (China) Organized in collaboration with Union of Chinese Lymphoma Investigators - UCLI
14:15	110	NON-CANONICAL ROLE OF EZH2 IN NK / T-CELL LYMPHOMA W.-J. Chng, Singapore (Singapore)
14:30	111	EBV-ASSOCIATED NODAL T AND NK-CELL LYMPHOMA SHOWS DISTINCT MOLECULAR SIGNATURE AND COPY NUMBER CHANGES W.-J. Chng, Singapore (Singapore)
14:45	112	NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS W.-L. Zhao, Shanghai (China)
15:00	113	TREATMENT OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (ENKTL) W.S. Kim, Seoul (South Korea)
15:15 – 15:35		COFFEE BREAK - inside Aula Magna (Lugano University) for attendees
15:35	114	FIRST-LINE L-ASPARAGINASE-BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE I/II EXTRANODAL NK/T-CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL Y.-Q. Song, Beijing (China)
15:50	115	CURRENT TREATMENT FOR NK/T CELL LYMPHOMA: SUN YAT-SEN UNIVERSITY CANCER CENTER EXPERIENCE, CHINA H.-Q. Huang, Guangzhou (China)
16:05	116	MOLECULAR CHARACTERIZATION OF EXTRANODAL NATURAL KILLER (NK)/T- CELL LYMPHOMAS, NASAL TYPE FROM LATIN AMERICA L. Quintanilla-Martinez, Tuebingen (Germany)
16:20	117	NK/T-CELL LYMPHOMA, THE FRENCH EXPERIENCE A. Jaccard, Limoges (France)
16:35		COMMENTS M. Federico, Modena (Italy), W.-Q. Jiang, Guangzhou (China) and X.-P. Lu, Shenzhen (China)
15:15 – 15:35 Marquee, Cinema Corso		COFFEE BREAK
15:35 – 15:50 Room A, B, Marquee and Cinema Corso		DESIGN OF FUTURE CLINICAL TRIALS: REPORT OF THE 14-ICML WORKSHOP Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland) A. Younes, New York, NY (USA)

15:50 – 17:20 Room A, B, Marquee and Cinema Corso		SESSION 9 – AGGRESSIVE LYMPHOMAS Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)
15:50	118	LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA K.E. Smedby, Solna (Sweden)
16:05	119	R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS T. Lamy, Rennes (France)
16:20	120	RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL>60 STUDY OF THE DSHNHL M. Pfreundschuh, Homburg (Germany)
16:35	121	DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): A PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REM ₀ DL-B A.J. Davies, Southampton (UK)
16:50	122	PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY U. Vitolo, Turin (Italy)
17:05	123	RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF A MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R K. Dunleavy, Bethesda, MD (USA)
17:30 – 18:45 Marquee		FAREWELL APERO

Saturday, June 17, 2017

08:00 – 10:30 Room 156 (Lugano University)		SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING A.K. Berthelsen, Copenhagen (Denmark) and L. Specht, Copenhagen (Denmark) Organized by International Lymphoma Radiation Oncology Group - ILROG and European Society for Radiotherapy and Oncology – ESTRO Compulsory pre-registration up to 30 attendees at registration@lymphcon.ch (fee CHF 50.-)
08:30 – 10:00		<i>2 parallel sessions</i>
Room A		SESSION 10 – IMMUNOTHERAPIES Co-chairs: R. Levy, Stanford, CA (USA) and D.G. Maloney, Seattle, WA (USA)
08:30	124	CD27 STIMULATION ENHANCES CD20 MAB THERAPY THROUGH ACTIVATION OF INNATE IMMUNITY S.H. Lim, Southampton (UK)
08:45	125	NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL M. Fanale, Houston, TX (USA)

09:00	126	PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY P.L. Zinzani, Bologna (Italy)
09:15	127	A PHASE Ib STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL) M.L. Palomba, New York, NY (USA)
09:30	128	HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001) J. Abramson, Boston, MA (USA)
09:45	129	A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) C. Sauter, New York, NY (USA)
Room B		SESSION 11 – MANTLE CELL LYMPHOMA Co-chairs: U. Novak, Bern (Switzerland) and G. Salles, Lyon (France)
08:30	130	P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK M. Dreyling, Munich (Germany)
08:45	131	FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY T. Hawkins, Auckland (New Zealand)
09:00	132	FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF A LYSA GROUP TRIAL R. Gressin, Grenoble (France)
09:15	133	IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: A WINDOW OF OPPORTUNITY TO REDUCE CHEMO M.L. Wang, Houston, TX (USA)
09:30	134	IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY S. Rule, Plymouth (UK)
09:45	135	COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY C.S. Tam, Melbourne (Australia)
10:00 – 10:15		BREAK
10:15 – 11:15 Room A and B		SESSION 12 – MARGINAL ZONE LYMPHOMA Co-chairs: A. Lopez-Guillermo, Barcelona (Spain) and S. Montoto, London (UK)
10:15	136	INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION M. Frigeni, Pavia (Italy)

10:30	137	IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN A SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL) M. Herold, Erfurt (Germany)
10:45	138	LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01) A. Salar, Barcelona (Spain)
11:00	139	PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA M. Coleman, New York, NY (USA)
11:15 – 11:40 Room A and B		14-ICML HIGHLIGHTS  “TAKE HOME MESSAGES” J.W. Friedberg, Rochester, NY (USA)
11:40 – 11:50		CLOSURE AND FAREWELL F. Cavalli, Bellinzona (Switzerland)
13:30 – 18:15 Room B		WORKSHOP - NEW DEVELOPMENTS IN CANINE LYMPHOMA Co-chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy) Organized by the European Canine Lymphoma Network open to all 14-ICML attendees

 This icon denotes presentations that will be available online, only for 14-ICML attendees, between July and September 2017, thanks to an unrestricted grant provided by Bristol-Myers Squibb.

- Updated on June 05, 2017 -